A Randomized Controlled Clinical Trial Comparing Belatacept With Tacrolimus After De Novo Kidney Transplantation
Authors:
- Carla C. BaanCarla C. Baan
- Marian C. Clahsen-Van GroningenMGMarian C. Clahsen-Van Groningen
- Rens KraaijeveldRKRens Kraaijeveld
- Marjolein DieterichMDMarjolein Dieterich
- Wenda VerschoorWVWenda Verschoor
- Jan H. von der ThusenJTJan H. von der Thusen
- Dave L. RoelenDRDave L. Roelen
- Monique CadoganMCMonique Cadogan
- Jacqueline van de WeteringJWJacqueline van de Wetering
- Joost van RosmalenJRJoost van Rosmalen
- Wilem WeimarWWWilem Weimar
- 1 October 2017
- journal article
- research article
- Published by Wolters Kluwer Health in Transplantation
- Vol. 101 (10) , 2571-2581
Abstract
Belatacept, an inhibitor of the CD28-CD80/86 co-stimulatory pathway, allows for calcineurin-inhibitor free immunosuppressive therapy in kidney transplantation but is associated with a higher acute rejection risk than ciclosporin. Thus, no biomarker for belatacept-resistant rejection has been validated. In this randomized controlled trial, acute rejection-rate was compared between belatacept- and tacrolimus-treated patients and immunological biomarkers for acute rejection were investigated. Forty kidney-transplant recipients were 1:1 randomized to belatacept or tacrolimus combined with basiliximab, mycophenolate mofetil and prednisolone. The 1-year incidence of biopsy-proven acute rejection was monitored. Potential biomarkers, namely CD8+CD28-, CD4+CD57+PD1- and CD8+CD28++ EMRA T cells were measured pre and posttransplantation and correlated to rejection. Pharmacodynamic monitoring of belatacept was performed by measuring free CD86 on monocytes. The rejection incidence was higher in belatacept-treated than tacrolimus-treated patients: 55% vs. 10%; p = 0.006. All 3 graft losses, due to rejection, occurred in the belatacept group. Although 4 of 5 belatacept-treated patients with >35 cells CD8+CD28++ EMRA T cells/μL rejected, median pretransplant values of the biomarkers did not differ between belatacept-treated rejectors and nonrejectors. In univariable Cox regressions, the studied cell subsets were not associated with rejection-risk. CD86 molecules on circulating monocytes in belatacept-treated patients were saturated at all time points. Belatacept-based immunosuppressive therapy resulted in higher and more severe acute rejection compared to tacrolimus-based therapy. This trial did not identify cellular biomarkers predictive of rejection. In addition, the CD28-CD80/86 co-stimulatory pathway appeared to be sufficiently blocked by belatacept and did not predict rejection.Keywords
This publication has 48 references indexed in Scilit:
- Meta-Analysis of Calcineurin-Inhibitor-Sparing Regimens in Kidney TransplantationJournal of the American Society of Nephrology, 2011
- Premature aging of circulating T cells in patients with end-stage renal diseaseKidney International, 2011
- Role of CMV in immune senescenceVirus Research, 2011
- Immunosuppression with Belatacept-Based, Corticosteroid-Avoiding Regimens in De Novo Kidney Transplant RecipientsAmerican Journal of Transplantation, 2010
- Selective Targeting of Human Alloresponsive CD8+ Effector Memory T Cells Based on CD2 ExpressionAmerican Journal of Transplantation, 2010
- Granzymes and perforin in solid organ transplant rejectionCell Death & Differentiation, 2009
- Alefacept promotes co-stimulation blockade based allograft survival in nonhuman primatesNature Medicine, 2009
- Impaired Immune Responses and Antigen-Specific Memory CD4+ T Cells in Hemodialysis PatientsJournal of the American Society of Nephrology, 2008
- Tacrolimus versus ciclosporin as primary immunosuppression for kidney transplant recipients: meta-analysis and meta-regression of randomised trial dataBMJ, 2005
- Racial differences in renal allograft survival: The role of systemic hypertensionKidney International, 1995